CD274 and neoplasm: The use of ICIs for some of the above indications is determined by the extent of the disease, the previous treatment regimen, the presence of biomarkers (expression of PD-L1, CPS, TPS, MSI-H, dMMR, tumor mutational burden, EGFR, and ALK alterations), and the concomitant administration of a certain cytostatic regimen and biologic therapy.